{"id":38057,"date":"2020-08-18T07:59:13","date_gmt":"2020-08-18T07:59:13","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=38057"},"modified":"2020-08-18T07:59:13","modified_gmt":"2020-08-18T07:59:13","slug":"gp120-protein","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/","title":{"rendered":"GP120 Protein"},"content":{"rendered":"<p>An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America&#8217;s Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America&#8217;s Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-38057","post","type-post","status-publish","format-standard","hentry","category-g"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GP120 Protein - Definition of GP120 Protein<\/title>\n<meta name=\"description\" content=\"An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America&#039;s Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GP120 Protein - Definition of GP120 Protein\" \/>\n<meta property=\"og:description\" content=\"An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America&#039;s Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-18T07:59:13+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/\",\"name\":\"GP120 Protein - Definition of GP120 Protein\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-08-18T07:59:13+00:00\",\"dateModified\":\"2020-08-18T07:59:13+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America's Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GP120 Protein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GP120 Protein - Definition of GP120 Protein","description":"An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America's Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/","og_locale":"en_US","og_type":"article","og_title":"GP120 Protein - Definition of GP120 Protein","og_description":"An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America's Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/","og_site_name":"Glossary","article_published_time":"2020-08-18T07:59:13+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/","name":"GP120 Protein - Definition of GP120 Protein","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-08-18T07:59:13+00:00","dateModified":"2020-08-18T07:59:13+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"An adhesion molecule (glycoprotein) on the envelope (surface membrane) of HIV (i.e., AIDS-causing) viruses that directly interacts with the CD4 protein on helper T cells; enabling the HIV viruses to bind to and infect helper T cells. In 1994, a group at America's Scripps Research Institute led by Dennis Burton and Carlos Barbas III announced that they had generated a recombinant human antibody to the GP120 protein; which neutralized more than 75% of HIV isolates that it was tested against. This advance holds the potential to someday lead to a vaccine against AIDS.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/gp120-protein\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"GP120 Protein"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/38057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=38057"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/38057\/revisions"}],"predecessor-version":[{"id":38058,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/38057\/revisions\/38058"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=38057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=38057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=38057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}